Exploring the Resistance Mechanism of Osimertinib and Monitoring the Treatment Response Using Plasma ctDNA in Chinese NSCLC Patients

被引：9
|
作者：
Shi, Y. [1 ,2 ]
Xing, P. [1 ,2 ]
Han, X. [3 ,4 ]
Wang, S. [5 ]
Liu, Y. [1 ,2 ]
Liu, P. [1 ,2 ]
Li, J. [1 ,2 ]
Chang, L. [5 ]
Guan, Y. [5 ]
Zhang, Z. [1 ,2 ]
Wu, D. [1 ,2 ]
Yao, J. [1 ,2 ]
Xin, Y. [5 ]
机构：
[1] Chinese Acad Med Sci, Canc Inst & Hosp, Dept Med Oncol, Beijing, Peoples R China
[2] Peking Union Med Coll, Beijing Key Lab Clin Study Anticanc Mol Targeted, Beijing, Peoples R China
[3] Chinese Acad Med Sci, Natl Canc Ctr, Canc Hosp, Dept Clin Lab, Beijing, Peoples R China
[4] Peking Union Med Coll, Beijing 100021, Peoples R China
[5] Geneplus Beijing Inst, Beijing, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
plasma ctDNA; non-small cell lung cancer; Resistance;
D O I：
10.1016/j.jtho.2018.08.875
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.13-18
引用
收藏
页码：S589 / S589
页数：1
相关论文
共 50 条
  • [31] Early detection of competing resistance mutations using plasma next-generation sequencing (NGS) in patients (pts) with EGER-mutant NSCLC treated with osimertinib.
    Guibert, Nicolas Marie
    Paweletz, Cloud
    Hu, Yuebi
    Feeney, Nora B.
    Plagnol, Vincent
    Poole, Valerie
    Jones, Greg
    Oxnard, Geoffrey R.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [32] EML4-ALK MONITORING OF CRIZOTINIB RESPONSE IN BLOOD PLATELETS AND PLASMA OF NSCLC PATIENTS
    Nilsson, Jonas
    Costa, Carlota
    Karachaliou, Niki
    Taron, Miquel
    Tannous, Bakhos
    Thunnissen, Erik
    Wurdinger, Thomas
    Rosell, Rafael
    Smit, Egbert
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S804 - S804
  • [33] Detection and monitoring of tumor-derived mutations in ctDNA using the UltraSEEK Lung Panel on the MassARRAY System in metastatic NSCLC patients
    van der Leest, Paul
    Janning, Melanie
    Rifaela, Naomi
    Azpurua, Maria L. Aguirre
    Kropidlowski, Jolanthe
    Loges, Sonja
    Lozano, Nicholas
    Sartori, Alexander
    Irwin, Darryl
    Lamy, Pierre-Jean
    Hiltermann, T. Jeroen N.
    Groen, Harry J.
    Pantel, Klaus
    van Kempen, Leon C.
    Wikman, Harriet
    Schuuring, Ed
    CANCER RESEARCH, 2022, 82 (12)
  • [34] Gene mutational profiling of Chinese EGFR-T790M mutation NSCLC patients required resistance to osimertinib by next generation sequencing
    Xu, C.
    Wang, W.
    Zhuang, W.
    Song, Z.
    Lin, G.
    Chen, X.
    Zhu, Y.
    Fang, M.
    Zhang, H.
    Wang, H.
    Zhang, J.
    Yu, Z.
    Chen, R.
    Guan, Y.
    Yi, X.
    Chen, Y.
    Chen, G.
    Lv, T.
    Song, Y.
    ANNALS OF ONCOLOGY, 2017, 28 : 125 - 125
  • [35] Osimertinib vs Standard of Care (SoC) EGFR-TKI as First-Line Treatment in Chinese Patients With EGFRm Advanced NSCLC
    Zhou, C.
    Cheng, Y.
    He, Y.
    Li, W.
    Zhang, H.
    Zhou, Q.
    Wang, B.
    Liu, C.
    Ramalingam, S.
    Walding, A.
    Saggese, M.
    Wang, J.
    Fan, M.
    Wu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S507 - S508
  • [36] Associations of ctDNA levels during neoadjuvant treatment with pathological response in patients with resectable NSCLC from the phase 3 AEGEAN trial
    Gale, Davina
    Zhu, Zhou
    Lai, Zhongwu
    Reck, Martin
    Harpole, David
    Taube, Janis M.
    Mitsudomi, Tetsuya
    Hochmair, Maximilian
    Winder, Thomas
    Urban, Laszlo
    Rodriguez-Cid, Jeronimo
    Chu, Quincy
    Chaft, Jamie
    Stewart, Ross
    Hodgson, Darren
    Doherty, Gary J.
    Heymach, John V.
    CANCER RESEARCH, 2024, 84 (07)
  • [37] Competitive evolution of NSCLC tumor clones and the drug resistance mechanism of first-generation EGFR-TKIs in Chinese NSCLC patients
    Deng, Qinfang
    Xie, Boxiong
    Wu, Leilei
    Ji, Xianxiu
    Li, Chao
    Feng, Li
    Fang, Qiyu
    Bao, Yuchen
    Li, Jialu
    Jin, Shengnan
    Ding, Chunming
    Li, Yixue
    Zhou, Songwen
    HELIYON, 2018, 4 (12):
  • [38] EGFR T790M Mutation Detection and Osimertinib Treatment Response Evaluation by Liquid Biopsy in Advanced NSCLC Patients
    Li, C.
    Liu, H.
    Zhang, B.
    Zhang, Z.
    Su, Y.
    Wang, C.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2141 - S2142
  • [39] Additional chemotherapy for EGFRm patients with the continued presence of plasma ctDNA EGFRm at week 3 after start of osimertinib first-line treatment (PACE).
    Stratmann, Jan Alexander
    Acker, Fabian
    Aspacher, Lukas
    Alt, Juergen
    Althoff, Friederike C.
    Heinzen, Sophie
    Goekbuget, Nicola
    Mueller, Ina
    Reiser, Lena
    Hehn, Sina
    Serve, Hubert
    Maenz, Martin
    Meyer, Frauke
    Sebastian, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [40] Monitoring Plasma EGFR Mutations during First Line Treatment with EGFR TKIs in NSCLC Patients
    Mohorcic, Katja
    Kern, Izidor
    Janzic, Urska
    Hitij, Nina Turnsek
    Rot, Mitja
    Cufer, Tanja
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S388 - S389
12345